SUN PHARMACEUTICAL INDUSTRIES
|
SUN PHARMACEUTICAL INDUSTRIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 35.32 | 13.64 | 12.10 | 15.69 | 11.11 |
| CEPS(Rs) | 46.22 | 23.13 | 18.19 | 26.01 | 20.68 |
| DPS(Rs) | 11.50 | 10.00 | 7.50 | 4.00 | 2.75 |
| Book NAV/Share(Rs) | 233.38 | 200.11 | 193.65 | 188.66 | 172.59 |
| Tax Rate(%) | 9.01 | 24.00 | 18.39 | 16.42 | 15.77 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.44 | 14.71 | 13.78 | 11.74 | 11.14 |
| EBIT Margin(%) | 12.90 | 6.86 | 4.78 | 8.94 | 7.75 |
| Pre Tax Margin(%) | 12.67 | 6.67 | 4.55 | 8.43 | 6.76 |
| PAT Margin (%) | 11.53 | 5.07 | 3.72 | 7.05 | 5.70 |
| Cash Profit Margin (%) | 14.94 | 8.26 | 7.10 | 10.50 | 8.81 |
| Performance Ratios | |||||
| ROA(%) | 11.85 | 5.20 | 3.54 | 6.58 | 5.17 |
| ROE(%) | 16.46 | 7.21 | 4.98 | 9.66 | 8.05 |
| ROCE(%) | 17.24 | 9.28 | 5.66 | 10.07 | 8.68 |
| Asset Turnover(x) | 1.03 | 1.03 | 0.95 | 0.93 | 0.91 |
| Sales/Fixed Asset(x) | 1.81 | 1.81 | 1.74 | 1.78 | 1.92 |
| Working Capital/Sales(x) | 3.72 | 3.81 | 4.30 | 3.73 | 4.10 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.55 | 0.55 | 0.58 | 0.56 | 0.52 |
| Receivable days | 53.89 | 53.09 | 54.88 | 56.22 | 54.10 |
| Inventory Days | 47.78 | 48.68 | 50.10 | 48.40 | 47.84 |
| Payable days | 174.10 | 149.21 | 158.71 | 152.86 | 206.74 |
| Valuation Parameters | |||||
| PER(x) | 27.84 | 67.07 | 49.38 | 22.44 | 43.14 |
| PCE(x) | 21.27 | 39.55 | 32.85 | 13.54 | 23.17 |
| Price/Book(x) | 4.21 | 4.57 | 3.09 | 1.87 | 2.78 |
| Yield(%) | 1.17 | 1.09 | 1.26 | 1.14 | 0.57 |
| EV/Net Sales(x) | 5.38 | 5.57 | 4.20 | 2.63 | 4.07 |
| EV/Core EBITDA(x) | 19.24 | 19.03 | 15.10 | 11.32 | 16.12 |
| EV/EBIT(x) | 24.67 | 46.73 | 47.88 | 16.25 | 27.08 |
| EV/CE(x) | 3.05 | 3.22 | 2.20 | 1.33 | 1.90 |
| M Cap / Sales | 5.37 | 5.68 | 4.28 | 2.57 | 3.96 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.53 | 15.39 | 2.01 | 12.98 | 10.03 |
| Core EBITDA Growth(%) | 8.50 | 21.36 | 22.31 | 3.99 | 13.75 |
| EBIT Growth(%) | 107.88 | 56.71 | -44.64 | 21.69 | 9.23 |
| PAT Growth(%) | 151.36 | 49.07 | -45.43 | 30.46 | 24.98 |
| EPS Growth(%) | 158.91 | 12.70 | -22.87 | 41.25 | 27.19 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.11 | 0.02 | 0.08 | 0.18 | 0.25 |
| Current Ratio(x) | 2.00 | 2.03 | 1.89 | 2.02 | 1.79 |
| Quick Ratio(x) | 1.47 | 1.51 | 1.33 | 1.51 | 1.34 |
| Interest Cover(x) | 55.70 | 36.19 | 20.79 | 17.55 | 7.86 |
| Total Debt/Mcap(x) | 0.03 | - | 0.03 | 0.10 | 0.09 |
Compare Financial Ratios of peers of SUN PHARMACEUTICAL INDUSTRIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,305.4 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| MANKIND PHARMA | ₹93,565.4 Cr | NA | NA | NA | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | 3% |
2.3% |
68.2% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
